Human genes exhibit different effects on fitness in cancer and normal cells. Here, 22 we present an evolutionary approach to measure the selection pressure on human genes, 23 using the well-known ratio of the nonsynonymous to synonymous substitution rate in 24 both cancer genomes (CN/CS) and normal populations (pN/pS). A new mutation-profile- 25 based method that adopts sample-specific mutation rate profiles instead of conventional 26 substitution models was developed. We found that cancer-specific selection pressure is 27 quite different from the selection pressure at the species and population levels. Both the 28 relaxation of purifying selection on passenger mutations and the positive selection of 29 driver mutations may contribute to the increased CN/CS values of human genes in cancer 30 genomes compared with the pN/pS values in human populations. The CN/CS values also 31 contribute to the improved classification of cancer genes and a better understanding of 32 the onco-functionalization of cancer genes during oncogenesis. The use of our 33 computational pipeline to identify cancer-specific positively and negatively selected 34 genes may provide useful information for understanding the evolution of cancers and 35 identifying possible targets for therapeutic intervention.
distinguishing synonymous from nonsynonymous somatic mutations is straightforward. 139 We developed the mutation-profile-based method to estimate the CN/CS ratio of each 140 human gene based on the mutation profiles of cancer somatic mutations and the pN/pS 141 ratio for germline substitutions. In contrast to the equal-rate method [27] , our method 142 considers differences in substitution rates and uses the overall mutation rate profile as 143 the weight matrix ( Figure 1 ). 144 We calculated the expected number of nonsynonymous and synonymous sites 145 based on the exonic mutation rate profiles. We then counted the number of 146 nonsynonymous and synonymous substitutions in the protein-coding region of each 147 human gene for all cancer somatic mutations or germline substitutions. A χ 2 test was 148 performed to identify the genes whose CN/CS values were either significantly greater 149 than one or less than one, which indicates positive or negative (purifying) selection, 150 respectively. Of the 16,953 genes with at least one germline substitution and cancer 151 8 somatic mutation, the overall CN/CS value for cancer somatic mutations 152 (mean±s.e.=1.199±0.008) was much greater than the overall pN/pS of germline 153 substitutions (mean±s.e.=0.738±0.005) (Wilcoxon test, p<2.2×10 -16 ) ( Table 1A, 154 Supplementary Table S1 ). In the cancer genomes, 365 genes had CN/CS values 155 significantly greater than one, and 923 genes had CN/CS values significantly less than 156 one (χ 2 test, p<0.01, FDR<0.1). By contrast, germline substitutions included only 24 157 genes with pN/pS values significantly greater than one, whereas 4,897 genes had pN/pS 158 values significantly less than one (χ 2 test, p<0.01, FDR<0.1). Of these 365 cancer 159 positively selected genes, only one gene (RSRC1) also exhibited positive selection 160 whereas 117 genes exhibited negative selection in germline substitutions. Additionally, 161 500 cancer negatively selected genes did not exhibit significant negative selection in 162 germline substitutions. These genes may therefore be under different selective pressure 163 in cancer and germline genomes. 164 Previous studies have attributed elevated CN/CS values to the relaxation of 165 purifying selection [16] or increased positive selection of globally expressed genes [17] . 166 Our results show that the number of genes under positive selection increased, whereas The Cancer Gene Census (CGC) [31, 32] Table S2 ). In addition, the 29 strong positively selected genes are 194 significantly enriched in biological processes related to cancer, according to the 195 10 functional analysis using DAVID v6.7 [36] ( Supplementary Table S3 ). Some cancer 196 genes also show negative selection in cancer genomes, such as the oncogene MLLT3 197 (CN/CS=0.11, p=3.14×10 -44 , FDR=5.52×10 -41 ). The MLL-MLLT3 gene fusion is the 198 main mutation type of MLLT3 that drives tumorigenesis in acute leukemia [37] . 199 Interestingly, MLLT3 has recurrent synonymous mutations at amino acid positions 166 200 to 168 (S166S, 8/9155; S167S, 33/9155; S168S, 23/9155).
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Using the CN/CS values, we classified known cancer genes according to the 202 selection pressure on these genes in cancer cells, as well as their onco-functionalization 203 in oncogenesis ( Table 2 ). The most important two classes are oncogenes and tumor 212 We also observed 12 cancer positively selected genes (p<10 -5 ) that have not been 213 reported as cancer-associated genes. These genes are recurrently mutated in several When we chose a more stringent cut-off of p<10 -5 for cancer negatively selected 218 genes, we found 112 genes that showed an enrichment in the Notch signaling pathway 219 ( Supplementary Table S3 ). Forty-seven of the 112 negatively selected genes showed 220 more stringent selective constraint in cancer cells than in normal cells (pN/pS > CN/CS, 221 p>0.05 for pN/pS). It would be quite valuable to uncover the roles of these evolutionarily 222 conserved genes in cancer cells. Out of the 47 genes, 14 genes showed a significantly 223 increased expression level in cancers than in normal tissues (fold change>2, p<10 -4 ) 224 ( Supplementary Table S4 ). For example, SPRR3, a member of the small proline-rich 225 protein family, is under purifying selection in cancer cells (CN/CS=0.27, p=5.73×10 -11 , 226 FDR=1.91×10 -8 ) and neutral selection in germline cells (pN/pS =0.88, p=0.75, 227 FDR=0.37). It has been reported that SPRR3 is overexpressed in several tumor types, 228 and is associated with tumor cell proliferation and invasion. Therefore, SPRR3 could 229 be a potential biomarker and novel therapeutic target [45] [46] [47] . 230 We also examined essential genes during human development and cancer 231 development. We extracted 2,452 human orthologs of mouse essential genes from 232 DEG10 (the Database of Essential Genes) [48]. These genes, which are human 233 orthologs of known essential genes in mice [49] , are critical for cell survival and are 234 therefore more conserved than other genes at the species and population levels. Here, 235 we found that human orthologs of mouse essential genes have significantly lower dN/dS 236 values (measured between human-mouse orthologs) and lower pN/pS values for 237 germline substitutions but similar CN/CS values for cancer somatic mutations compared 238 with the values for non-essential genes (Table 1A) . Human orthologs of mouse essential 239 12 genes are also enriched among cancer positively selected genes. Eighteen of the twenty-240 nine (62.1%) positively selected genes (p<10 -5 ) are human orthologs of mouse essential 241 genes ( Supplementary Table S2 ). We also used the human orthologs of mouse essential 242 genes from OGEE (the database of Online GEne Essentiality) [50] to confirm these 243 results ( Supplementary Table S2 ). (Table 1A) , suggesting a functional shift of these genes in 251 human populations and cancer cells. 252 We further tested the correlations of the dN/dS, pN/pS and CN/CS values of human 253 genes for human-mouse orthologs, germline substitutions and cancer somatic mutations 254 to compare selective pressures among species, populations and cancer cells (Table 1B) . Selection pressure among different cancer types 262 As cancer is highly heterogeneous, we further analyzed the selection pressure of 263 human genes in different cancer types. The 9,155 tumor samples from the ICGC 264 database could be classified as 20 cancer types according to the primary site. The 265 overall CN/CS values for the cancer somatic mutations in the different cancer types 266 ranged from 1.078±0.022 to 1.827±0.013 (mean±s.e., Table 3 ). The detected positively 267 and negatively selected genes (χ 2 test, p<0.01) varied in the different cancer types 268 ( Supplementary Table S5 ). Due to the limited number of tumor samples and somatic 269 mutations for each cancer type, particularly in the cancer types with low mutation rates, 270 our method might not be sensitive enough to detect the selection pressure for each gene.
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For example, only one positively selected gene was detected in bone cancer (IDH1) and 272 nervous system cancer (ALK), respectively. There were also three genes (TP53,
273
PIK3CA and KRAS) that showed positive selection in more than five cancer types. In 274 particular, TP53 showed positive selection in 15 cancer types. On the other hand, more 275 genes (164/188, 87.2%) were under positive selection in only one cancer type. We also 276 found that six genes (TBP, EP400, DSPP, MUC21, MLLT3, and MUC2) were under 277 negative selection in more than five cancer types. These genes also showed negative 278 selection at the species and population levels. Furthermore, 85.8% (2,417/2,817) of 279 genes showed negative selection in only one cancer type. These results indicate the 280 divergence of selection pressure in different cancer types. Supplementary Table S1 ) but lower than that calculated using the mutation-profile- 289 based method (Wilcoxon test, p<2.2×10 -16 ) ( Figure 3A) . Consequently, the number of 290 genes with CN/CS values >1 (χ 2 test, p<0.01, FDR<0.1) is much lower than those 291 calculated using the exonic mutation profiles (37 versus 365), whereas the number of 292 genes with CN/CS values <1 (χ 2 test, p<0.01, FDR<0.1) is much greater (2851 versus 293 923) ( Figure 3B and 3C) . 294 We also used the intergenic mutation rate profile from 2,900 tumor-normal whole 295 genome sequences, which are included in the 9,155 cancer samples of ICGC database, 296 to calculate the CN/CS value for cancer somatic mutations. The overall CN/CS value 297 (mean±s.e.=1.503±0.010) is greater than that calculated from the exonic mutation rate 298 profile (mean±s.e.=1.199±0.008) (Wilcoxon test, p<2.2×10 -16 ), resulting in more 299 positively selected genes (1526 versus 365) and fewer negatively selected genes (298 300 versus 923) ( Figure 3B and 3C) .
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The equal-rate method ignores the mutation rate bias between different substitution 302 types, especially the ratio of transition to transversion, leading to underestimation of 303 the CN/CS ratio. Therefore, the equal-rate method is strict for positive selection detection 304 but relaxed for the detection of negative selection [52] . In contrast, the mutation-profile-305 15 based method considers the mutation bias, which can be depicted as the internal 306 variance between mutation rates of different substitution types. Thus, the mutation-307 profile-based method can correct the underestimation of the CN/CS ratio estimated by 308 the equal-rate method. Furthermore, the mutation-profile-based method would also 309 increase the false-positive results for detecting positively selected genes but be more profiles are well known to be heterogeneous among different cancer types, even for 350 samples with the same tissue origin [19, 20, 28, 35] . As the number of sequenced cancer 351 genomes increases, we will be able to classify cancer samples by their specific mutation 352 profiles and infer evolutionarily selective pressures more precisely using the mutation- [52]. The mutation-profile-based method is more sensitive for the detection of positive 364 selection but more conservative for the detection of negative selection compared with 365 the equal-rate method. As more tumor-normal whole genome sequence data become 366 available, it would be better to choose suitable mutation profiles for the mutation-367 profile-based method. With the expansion of these data in the future, we may apply 368 more precise methods to identify neutral background mutation properties. Statistical measure for gene-specific selection pressure in cancer evolution (CN/CS) 395 In cancer genomics, distinguishing synonymous from nonsynonymous somatic 396 mutations is straightforward. Thus, given a set of independent cancer samples, the ratio 
